Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.

International journal of clinical pharmacology and therapeutics - 1 Jan 2007

Kuhn U D, Kirsch M, Merkel U, Eberhardt A M, Wenda B, Maurer I, Härtter S, Hiemke C, Volz H P, Balogh A

Abstract excerpt

OBJECTIVES: The noradrenaline-selective antidepressant reboxetine in vitro is a weak inhibitor of both cytochrome P450 (CYP) 2D6 and CYP3A4. Thus, in this study the pharmacokinetics of reboxetine in relation to pharmacogenetics and the effects of reboxetine compared to paroxetine treatment on the CYP2D6 and CYP3A4 phenotype were analyzed in healthy control subjects. METHODS: Healthy male volunteers were treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme Inhibitors

Share to Dextromethorphan

Share to Drug Interactions

Share to Morpholines

Share to Paroxetine

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 17256449
DOI: 10.5414/cpp45036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.PMID 17256449Read ↗

No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.Semantic proximity Read ↗

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.Semantic proximity Read ↗

Newer antidepressants and the cytochrome P450 system.Semantic proximity Read ↗

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.Semantic proximity Read ↗

Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.Semantic proximity Read ↗

In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma.Semantic proximity Read ↗

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.Semantic proximity Read ↗

Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.Semantic proximity Read ↗

Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.Semantic proximity Read ↗

Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4.Semantic proximity Read ↗

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.Semantic proximity Read ↗

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.